Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v6-FR
Language French French
Date Updated 2024-10-01 2024-07-02
Drug Identification Number 02046210 02046210
Brand name LUTREPULSE PWS 0.8MG/VIAL LUTREPULSE PWS 0.8MG/VIAL
Common or Proper name GONADORELIN ACETATE GONADORELIN ACETATE
Company Name FERRING INC FERRING INC
Ingredients GONADORELIN ACETATE GONADORELIN ACETATE
Strength(s) 0.8MG 0.8MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 1 x 10 mL vial of 0.8 mg 1 x 10 mL vial of 0.8 mg
ATC code H01CA H01CA
ATC description HYPOTHALAMIC HORMONES HYPOTHALAMIC HORMONES
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2024-06-30 2024-06-30
Actual start date 2024-06-30 2024-06-30
Estimated end date Unknown Unknown
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Lutrapulse 0.8mg is no longer available worldwide beyond June 30, 2024 due to expiry dating of existing supply. No new product will be manufactured or is available due to manufacturing line decommissioning. Lutrapulse 0.8mg is no longer available worldwide beyond June 30, 2024 due to expiry dating of existing supply. No new product will be manufactured or is available due to manufacturing line decommissioning.
Health Canada comments